The content of matrix metalloproteinases in bladder cancer tumors

V. Dmytryk, O. Savchuk, I. Andriychenko
Taras Shevchenko National University of Kyiv, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv; "Biopharma" Limited, Kyiv


Bladder cancer (BC) is the 9th in frequency oncologic disease, with the highest number of patients in developed countries. The disease is more
commonly diagnosed in men – about 75%. The ability to invade surrounding tissues and metastasis to individual organs is one of the fundamental properties of malignant tumors. According to modern ideas about mechanisms of metastasis, basement membranes and extracellular matrix are the main barriers, and tissue structures are needed to overcome the invasive growth of tumor cells. Almost all of the extracellular matrix components can be destroyed by the use of metal-matrix proteinases (MMP), moreover, the precursors of growth factors and adhesion molecules on the cell surface may be the MMP substrates. MMPs also participate in epithelial-mesenchymal transformation, which provides metastasis. Previous studies by other authors point to an increase in the biosynthesis of various MMPs in the outbreak of tumors and in metastases, such changes associated with the degree of differentiation of the tumor, the depth of the invasion, as well as their association with poor further prognosis and low survival rates in patients with various cancers. The purpose of our work was to investigate the content of MMP-1, 2, 3, 8 and TIMP-1 in the tumors and walls of the healthy bladder in patients with BC, depending on the stage of TNM classification. We investigated the increase in the content of MMP-1, 2, 3, 8 and TIMP-1 in samples of healthy bladder walls for stage 3 and 4 of the BC, indicating the participation of the investigated parameters in the growth and invasion of bladder tumors. The results of our study are consistent with the results of previous studies conducted in the study of other neoplasms, which indicate the relationship between the studied parameters with the development of cancer.


bladder cancer, MMP, TIMP, ELISA

Full Text:



Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2(10): 737-744.

Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72(1): 248-254.

Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25(1): 9–34.

Duffy M.J., McGowan P.M., Gallagher W.M. Cancer invasion and metastasis: changingviews. J Pathol 2008, 214(3):283–293.

Duffy M.J. Proteases as prognostic markers in cancer. Clin Cancer Res 1996, 2(4):613–618.

Hegedus L., Cho H., Xie X., Eliceiri G.L. (2008) Additional MDAMB-231 breast cancer cell matrix metalloproteinases promote invasiveness. Journal of Cellular Physiology 216(2): 480-485.

Heljasvaara R., Nyberg P., Luostarinen J. et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Experimental Cell Research. 2005;307(2):292–304.

Ishchuk T., Glavachek D., Savchuk O., Yakovlev P., Falaleeva T., Beregova T., Ostapchenko L. (2018). Plasma levels of MMPs and TIMP-1 in urinary bladder cancer patients. Biomedical Research and Therapy. 5. 1931-1940. 10.15419/bmrat.v5i1.407.

Koc M., Ediger D., Budak F., Karadag M., Oral H.B., Uzaslan E., Ege E., Gozu R.O. (2006). Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 92(2): 149-154.

Malemud C. J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006, 11: 1696–1701.

Mannello F., Luchetti F., Falcieri E., Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis. 2005;10(1):19–24.

McCawley L.J., Crawford H.C., King L.E., Jr., Mudgett J., Matrisian L.M. (2004). A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Research 64(19): 6965-6972.

Naruo S., Kanayama H., Takigawa H., Kagawa S., Yamashita K., Hayakawa T. Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. International Journal of Urology. 1994; 1(3): 228–231.

Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18(5):1135–1149.

Nutt J.E., Mellon J.K., Qureshi K., Lunec J. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. British Journal of Cancer. 1998; 78(2): 215–220.

Ramnath N., Creaven P.J.: Matrix metalloproteinase inhibitors. Curr Oncol Rep. 2004, 6(2): 96–102.

Roy R., Louis G., Loughlin K.R., Wiederschain D., Kilroy S.M., Lamb C.C., Zurakowski D., Moses M.A. (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clinical cancer research: An official journal of the American Association for Cancer Research 14(20): 6610- 6617.

Stadlmann S., Pollheimer J., Moser P.L., Raggi A., Amberger A., Margreiter R. et al. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur J Cancer. 2003; 39:2499–2505.

Thiery J.P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer 2(6): 442-454.

Thirkettle S., Decock J., Arnold H., Pennington C. J., Jaworski D. M. & Edwards D. R. (2013). Matrix metalloproteinase 8 (collagenase 2) induces the expression of interleukins 6 and 8 in breast cancer cells. The Journal of biological chemistry, 288(23), 16282–16294. doi:10.1074/jbc.M113.464230.

Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92(8):827–839.

Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13(8): 781–792.

Zhang W., Wang F., Xu P., Miao C., Zeng X., Cui X., Lu C., Xie H., Yin H., Chen F., et al. Perfluorooctanoic acid stimulates breast cancer cells invasion and up-regulates matrix metalloproteinase-2/-9 expression mediated by activating NF-κB. Toxicol Lett. 2014; 229:118–125.

Zhang Y., Chen Q. Relationship between matrix metalloproteinases and the occurrence and development of ovarian

cancer. Braz J Med Biol Res. 2017 May 18; 50(6): e6104

Received: 07.03.2019

Revised: 09.04.2019

Signed for the press: 09.04.2019



  • There are currently no refbacks.

Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).